Private Equity Round in 2018
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.
Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Private Equity Round in 2014
Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality. Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide. Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases.
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.
Private Equity Round in 2013
Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality. Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide. Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases.
Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinical reality. Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide. Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan.
MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in multiple clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor for use in combination with fluconazole for serious fungal infections which has completed Phase I clinical studies; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is currently in a Phase II trial in refractory or relapsed follicular lymphoma. Mocetinostat is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent for neurodegenerative diseases has successfully completed Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.
Aires Pharmaceuticals, Inc., a clinical stage pharmaceutical company, develops therapies to treat pulmonary disorders. The company offers Aironite, an inhaled drug that is used to treat adult and pediatric pulmonary hypertension, cystic fibrosis, pneumonia, and other respiratory infections. It also develops products for the treatment of bacterial pulmonary infections. Aires Pharmaceuticals was founded in 2006 and is based in San Diego, California.
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known as IntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California.
Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient. Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.
Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.
ORTHOCON is a medical therapeutics company developing innovative absorbable products for orthopaedic and spine surgeries.
Gloucester Pharmaceuticals is a biopharmaceutical company owned by [Celgene](/organization/celgene) that acquires clinical-stage oncology drug candidates with the goal of advancing them through regulatory approval and commercialization. Gloucester's first compound, romidepsin, is a late-stage oncology drug candidate that has shown potential activity across a range of hematological malignancies. The Company retains worldwide exclusive rights to romidepsin, an oncology candidate within a new class of anti-cancer agents known as histone deacetylase (HDAC) inhibitors. Preclinical studies suggest that romidepsin is a potent inhibitor of Class I, Class II and Class IV HDACs.
BioSyntech, Inc. develops biotherapeutic thermogels designed for tissue repair and delivery of therapeutic agents. Its technology platform is BST-Gel, a family of hydrogels based on chitosan, a natural biopolymer derived from crustacean shells. The company’s lead products in clinical trials include BSTCarGel for cartilage repair; BST-DermOn for wound healing; and BST-InPod for the treatment of chronic pain due to plantar fat pad atrophy in the heel and forefoot. Biosyntech has a collaboration with Nicholas Piramal India, Ltd. to involve in the clinical studies for BST-InPod, which is being developed to alleviate the chronic pain associated with foot fat pads. The company was incorporated in 1994 and is headquartered in Laval, Canada.
Zosano Pharma focuses on creating better products with its innovative drug delivery technology. Zosano's objective is to discover and develop therapeutic drug candidates that address large unmet medical needs or have a significant potential for commercialization. It was founded in 2006 and headquartered in Fremont, California.
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.
ORTHOCON is a medical therapeutics company developing innovative absorbable products for orthopaedic and spine surgeries.
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases.
Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients. Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.
Excaliard is a newly formed, venture capital-funded biotechnology company focused on the development and commercialization of antisense drugs for the local treatment of scarring and other fibrotic diseases.
Zosano Pharma focuses on creating better products with its innovative drug delivery technology. Zosano's objective is to discover and develop therapeutic drug candidates that address large unmet medical needs or have a significant potential for commercialization. It was founded in 2006 and headquartered in Fremont, California.
LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule IND candidates against clinically validated therapeutic targets, focused primarily on the treatment of Cancer and infectious diseases.
5asec is a textile care brand that provides its customers with dry cleaning and laundry services. 5asec provides its services in 3 segments, including basic services: dry cleaning, professional washing and steam ironing, and stain cleaning; professional services: duvet and home linen treatment, alterations services; and carpets, furniture, and leather cleaning; and textile care solutions: maxima treatment, appret finish, anti-moth and dust mites’ repellent solutions, and water repellent treatments. 5asec is headquartered in Geneva, Switzerland.
Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.
Alaunos Therapeutics is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.
NovaDel Pharma Inc
Venture Round in 2006
NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary oral spray technology delivery system offers the patient the potential for (i) more rapid delivery of drugs to the bloodstream allowing for quicker onset of therapeutic effects compared to conventional oral dosage forms; (ii) increased bioavailability of a drug by avoiding metabolism by the liver; (iii) improved drug safety profile by reducing the required dosage, including possible reduction of side effects; (iv) improved dosage reliability; (v) allowing medication to be taken without water; (vi) avoiding the need to swallow as is the case with many medications; and (vii) improved patient convenience and compliance. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies.
Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.
Alaunos Therapeutics is a biotechnology company employing a novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications. It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Guava Technologies, Inc. develops, designs, and manufactures biotechnology and medical devices. Its products include HIV/AIDS monitoring, viacount cell counting and viability assay, antibody quantification assay, apoptosis assay suite, cell cycle assay, cytotoxicity assay, cell proliferation assay, and benchtop cell analysis systems. Guava Technologies also offers flow cytometry systems for cell biology research, drug discovery and development, and HIV/AIDS monitoring. It serves life science research, drug discovery and development, cell biology research, core flow cytometry, and clinical diagnostics markets. The company's products are used in cell counting/viability, antibody quantification, cell cycle and proliferation, cytotoxicity, and apoptosis applications. Guava Technologies, Inc. was founded in 1998 and is headquartered in Hayward, California. As of February 20, 2009, Guava Technologies, Inc. operates as a subsidiary of Millipore Corp.
Founded in March 2006, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.
Gloucester Pharmaceuticals is a biopharmaceutical company owned by [Celgene](/organization/celgene) that acquires clinical-stage oncology drug candidates with the goal of advancing them through regulatory approval and commercialization. Gloucester's first compound, romidepsin, is a late-stage oncology drug candidate that has shown potential activity across a range of hematological malignancies. The Company retains worldwide exclusive rights to romidepsin, an oncology candidate within a new class of anti-cancer agents known as histone deacetylase (HDAC) inhibitors. Preclinical studies suggest that romidepsin is a potent inhibitor of Class I, Class II and Class IV HDACs.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.
As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.
Conforma Therapeutics
Series C in 2003
Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer. It develops drugs that induce tumor cells to degrade the proteins that promote cancer growth. The company offers HSP90 and CNF1010 which are used for the treatment of cancer. The company was incorporated in 1999 and is based in San Diego, California
Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, enable new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was incorporated in 1997 and is based in Gaithersburg, Maryland. Intercell USA, Inc. was formerly known as Iomai Corporation. As a result of the acquisition of Iomai Corporation by Intercell Ag, Iomai Corporation's name was changed. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Intercell Biomedical Research & Development AG.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.
Pharmion is a global biotech company that is dedicated to the hematology and oncology communities. We work in partnership with a network of scientific and clinical advisors to identify and develop products for global hematology and oncology markets. To expand each product's potential, we have established our own regulatory, development and sales and marketing organizations in the United States, Europe, and Australia, and we have developed a third-party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East, Asia, and Latin America. The global capabilities within our sales, marketing and distribution organization distinguishes us from other companies of a similar size. With our international network we can reach physicians and their patients in more than 30 countries. With proven development and regulatory professionals and an experienced global commercialization team, we concentrate our resources on licensing, developing, and commercializing therapeutic products for the treatment of hematology and oncology patients. Through these efforts, we seek to provide greater therapeutic options to hematologists and oncologists with the ultimate goal of extending survival and improving patients’ quality of life.
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.
Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.
Guava Technologies, Inc. develops, designs, and manufactures biotechnology and medical devices. Its products include HIV/AIDS monitoring, viacount cell counting and viability assay, antibody quantification assay, apoptosis assay suite, cell cycle assay, cytotoxicity assay, cell proliferation assay, and benchtop cell analysis systems. Guava Technologies also offers flow cytometry systems for cell biology research, drug discovery and development, and HIV/AIDS monitoring. It serves life science research, drug discovery and development, cell biology research, core flow cytometry, and clinical diagnostics markets. The company's products are used in cell counting/viability, antibody quantification, cell cycle and proliferation, cytotoxicity, and apoptosis applications. Guava Technologies, Inc. was founded in 1998 and is headquartered in Hayward, California. As of February 20, 2009, Guava Technologies, Inc. operates as a subsidiary of Millipore Corp.
Acurian provides solutions needed to recruit, enroll, and retain patients for clinical trials. The company offers recruitment feasibility, site identification and selection, patient recruitment and retention, and cancer solutions. Acurian was founded in 1998 and is based in Horsham, Pennsylvania.